Fig.1

IN THE PRESENCE OF IL-6 (0.1 ng/m1)




Fig.2

IN THE PRESENCE OF IL-6 (1 ng/ml)





Fig. 3


IN THE PRESENCE OF IL-6 (0.1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)

Fig.4

IN THE PRESENCE OF IL-6 (1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)

Fig.5

IN THE PRESENCE OF IL-6 (0.1 ng/ml)






Fig.6
IN THE PRESENCE OF IL-6 (1 ng/ml)



CONCENTRATION OF ANTI-HUMAN IL-6 RECEPTOR ANTIBODY (µg/ml)



- hPM1 (+) MELPHALAN (+) hPM1 (+) MELPHALAN (-) hPM1 (-) MELPHALAN (+) hPM1 (-) MELPHALAN (-)






Fig.9



```
hPM1 (+) MELPHALAN (+)
hPM1 (+) MELPHALAN (-)
hPM1 (-) MELPHALAN (+)
hPM1 (-) MELPHALAN (-)
```








Fig. 12



Fia.13

COMBINED USE OF MELPHALAN, DAY 42



BARS REPRESENT MEAN + S.E.




Fig.15

